OTTAWA, Feb. 21 /CNW Telbec/ - Health Canada is informing Canadians of
new information submitted by the manufacturer of the antiviral drug Baraclude
that suggests the drug may be linked to the development of a
treatment-resistant strain of HIV in one patient with HIV.
